Inven2 10th anniversary
Inven2 is 10 years in 2020.. ‘I’m proud of what we have achieved over these ten years. I’m particularly proud of the fact that we have contributed to ploughing NOK 500 million back into new research and innovation,’ says Ole Kristian Hjelstuen, CEO of Inven2.
Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on a new form of cancer...
The Dutch medical device company SJJ Solutions, the Department of Ophthalmology at Oslo University Hospital and the Laboratory of Adaptive Immunity...
Inven2’s core business is innovation. We contribute in the process of commersialising good ideas from talented researchers, turning them into products and services that make a difference.
Inven2 work closely with hospitals and companies to make sure clinical studies are completed quick and efficient, to the best for Norwegian patients.
Key figures 2010 – 2020
# Ideas evaulated (DOFI)
# Companies established
# Licence agreements
# New patent applications
MNOK transferred back to research, innovation and inventors
# Clinical Trials managed